Literature DB >> 16055673

Assessment of the influence of histaminergic actions on cocaine-like effects of 3alpha-diphenylmethoxytropane analogs.

Vera C Campbell1, Theresa A Kopajtic, Amy Hauck Newman, Jonathan L Katz.   

Abstract

Previous studies demonstrated that analogs of benztropine (BZT) possess high affinity for the dopamine (DA) transporter (DAT) but generally have behavioral effects different from those of cocaine, suggesting either unique actions at the DA transporter or that another action of these drugs interferes with cocaine-like effects. Because the parent compound has histamine-antagonistic effects, the affinity of its analogs for histamine H(1), H(2), and H(3) receptors were compared with DA transporter affinity to assess whether those differences predicted the amount of cocaine-like activity. All of the compounds displaced [(3)H]mepyramine from H(1), [(125)I]iodoaminopotentidine from H(2), and [(3)H]N-alpha-methylhistamine from H(3) histamine receptors with affinities ranging from 15.7 to 37,600, 218 to >4430, and 4040 to >150,000 nM, respectively. Affinities at histamine H(1) receptors were, respectively, approximately 25- or 300-fold greater than those at H(2) or H(3) histamine receptors. Relative affinities for H(1) and DAT binding did not reliably predict the degree of cocaine-like stimulation of locomotor activity. In addition, interactions of various histaminic agents with cocaine assessed whether an action at any of the histamine sites could interfere with cocaine-like effects. None of the histaminic agents fully substituted for cocaine in rats trained to discriminate 10 mg/kg cocaine from saline nor did any of the compounds antagonize or otherwise diminish the discriminative stimulus effects of cocaine. The results suggest that affinity for histamine receptors cannot account for the diminished cocaine-like effects of the BZT analogs and suggest alternatively that these compounds have actions different from those of cocaine but likely mediated by their interaction with the DAT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16055673     DOI: 10.1124/jpet.105.090829

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

1.  Preference for distinct functional conformations of the dopamine transporter alters the relationship between subjective effects of cocaine and stimulation of mesolimbic dopamine.

Authors:  Stephen J Kohut; Takato Hiranita; Soo-Kyung Hong; Aaron L Ebbs; Valeria Tronci; Jennifer Green; Linda Garcés-Ramírez; Lauren E Chun; Maddalena Mereu; Amy H Newman; Jonathan L Katz; Gianluigi Tanda
Journal:  Biol Psychiatry       Date:  2014-04-19       Impact factor: 13.382

2.  Novel C-1 substituted cocaine analogs unlike cocaine or benztropine.

Authors:  Maarten E A Reith; Solav Ali; Audrey Hashim; Imran S Sheikh; Naresh Theddu; Narendra V Gaddiraju; Suneet Mehrotra; Kyle C Schmitt; Thomas F Murray; Henry Sershen; Ellen M Unterwald; Franklin A Davis
Journal:  J Pharmacol Exp Ther       Date:  2012-08-15       Impact factor: 4.030

3.  Behavioral economic analysis of the effects of N-substituted benztropine analogs on cocaine self-administration in rats.

Authors:  Claudio Zanettini; Derek S Wilkinson; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2017-09-21       Impact factor: 4.530

4.  Relations between stimulation of mesolimbic dopamine and place conditioning in rats produced by cocaine or drugs that are tolerant to dopamine transporter conformational change.

Authors:  Gianluigi Tanda; Su Min Li; Maddalena Mereu; Alexandra M Thomas; Aaron L Ebbs; Lauren E Chun; Valeria Tronci; Jennifer L Green; Mu-Fa Zou; Theresa A Kopajtic; Amy Hauck Newman; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2013-04-24       Impact factor: 4.530

5.  Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist.

Authors:  Rajeev I Desai; David K Grandy; Carl R Lupica; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2013-11-05       Impact factor: 4.030

Review 6.  Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction.

Authors:  Richard B Rothman; Michael H Baumann; Thomas E Prisinzano; Amy Hauck Newman
Journal:  Biochem Pharmacol       Date:  2007-08-09       Impact factor: 5.858

7.  Effects of the H3 receptor inverse agonist thioperamide on cocaine-induced locomotion in mice: role of the histaminergic system and potential pharmacokinetic interactions.

Authors:  Christian Brabant; Livia Alleva; Thierry Grisar; Etienne Quertemont; Bernard Lakaye; Hiroshi Ohtsu; Jian-Sheng Lin; Peter Jatlow; Marina R Picciotto; Ezio Tirelli
Journal:  Psychopharmacology (Berl)       Date:  2008-10-09       Impact factor: 4.530

8.  2-isoxazol-3-phenyltropane derivatives of cocaine: molecular and atypical system effects at the dopamine transporter.

Authors:  Takato Hiranita; Derek S Wilkinson; Weimin C Hong; Mu-Fa Zou; Theresa A Kopajtic; Paul L Soto; Carl R Lupica; Amy H Newman; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2014-02-11       Impact factor: 4.030

9.  Super-additive interaction of the reinforcing effects of cocaine and H1-antihistamines in rhesus monkeys.

Authors:  Zhixia Wang; William L Woolverton
Journal:  Pharmacol Biochem Behav       Date:  2008-10-07       Impact factor: 3.533

10.  Behavioral and neurochemical effects of cocaine and diphenhydramine combinations in rhesus monkeys.

Authors:  Matthew L Banks; Monica L Andersen; Kevin S Murnane; Rebecca C Meyer; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2009-05-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.